H. Lundbeck specializes in the development, production and marketing of medicines for the treatment of psychiatric and neurological disorders. Net sales break down by family of products as follows:
- antidepressants and anti-anxiolitics (43,3%): marketed under the Cipralex and Lexapro brands;
- treatments for Alzheimer's disease (18,9%): Ebixa brand;
- other (37,8%): medicines for Parkinson's disease, sleep disorders, etc.
The group also had, at the end of 2012, a portfolio of 6 psychiatric products in development phase (including 4 in phase III and 2 in phase II).
Net sales break down geographically as follows: Europe (54,6%), the United States (18,9%) and other (26,5%).